Safety and efficacy of supported, at-home, sublingual ketamine telehealth for depression: New findings from a large, open-label effectiveness trial.
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Our aim for the present study is to replicate previous analysis of supported, at-home, sublingual ketamine telehealth for depression in a substantially larger patient sample (n ~ 10,000) obtained through ongoing data collection with the same telemedicine platform and to further clarify the safety and efficacy of this therapeutic modality. Building on the previous findings, we will investigate new data including the average ketamine dose prescribed to patients, the qualifications of ketamine prescribers (e.g., degree types), and characteristics/outcomes for patients who opted for a second round of ketamine treatment. We will also utilize longitudinal trajectory and network analyses to further describe the overall study population and to explore predictors of treatment outcome, which could inform personalized clinical decision-making with ketamine.
Fields of Study & Subjects
Treatment of Major Depression
Electroconvulsive Therapy Studies
Telemedicine and Telehealth Implementation
Publication details
- Journal / source
- OSF Preprints (OSF Preprints)
- Publication date
- 24 March 2026
- Language
- EN
- Document type
- Preprint